PncAgene expression and prediction factors on pyrazinamide resistance in Mycobacterium tuberculosis
© Untiveros and Sheen; licensee BioMed Central Ltd. 2014
Published: 1 October 2014
Mutations in the pyrazinamidase (PZAse) coding gene, pncA, have been considered as the main cause of pyrazinamide (PZA) resistance in Mycobacterium tuberculosis. However, recent studies suggest there is no single mechanism of resistance to PZA. The pyrazinoic acid (POA) efflux rate is the basis of the PZA susceptibility Wayne test, and its quantitative measurement has been found to be a highly sensitive and specific predictor of PZA resistance. Based on biological considerations, the POA efflux rate is directly determined by the PZAse activity, the level of pncA expression, and the efficiency of the POA efflux pump system. This study analyzes the individual and the adjusted contribution of PZAse activity, pncA expression and POA efflux rate on PZA resistance.
Thirty M. tuberculosis strains with known microbiological PZA susceptibility or resistance were analyzed. For each strain, PZAse was recombinantly produced and its enzymatic activity measured. The level of pncA mRNA was estimated by quantitative real time PCR, and the POA efflux rate was determined. Mutations in the pncA promoter were detected by DNA sequencing. All factors were evaluated by multiple regression analysis to determine their adjusted effects on the level of PZA resistance.
Results and conclusions
Low level of pncA expression associated to mutations in the pncA promoter region was observed in pncA wild-type resistant strains. POA efflux rate was the best predictor after adjusting for the other factors, followed by PZAse activity.
These results suggest that tests which rely on pncA mutations or PZAse activity are likely to be less predictive of real PZA resistance than tests which measure the rate of POA efflux. This should be further analyzed in light of the development of alternate assays to determine PZA resistance.
- Wade MM, Zhang Y: Mechanisms of drug resistance in Mycobacterium tuberculosis. Front Biosci. 2004, 9: 975-994. 10.2741/1289.View ArticlePubMedGoogle Scholar
- Zhang Y, Wade MM, Scorpio A, Zhang H, Sun Z: Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother. 2003, 52 (5): 790-795. 10.1093/jac/dkg446.View ArticlePubMedGoogle Scholar
- Zhang Y, Scorpio A, Nikaido H, Sun Z: Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Bacteriol. 1999, 181 (7): 2044-2049.PubMed CentralPubMedGoogle Scholar
- Zimic M, Fuentes P, Gilman RH, Gutierrez AH, Kirwan D, Sheen P: Pyrazinoic acid efflux rate in Mycobacterium tuberculosis is a better proxy of pyrazinamide resistance. Tuberculosis. 2012, 92 (1): 84-91. 10.1016/j.tube.2011.09.002.PubMed CentralView ArticlePubMedGoogle Scholar
- Zimic M, Loli S, Gilman RH, Gutierrez A, Fuentes P, Cotrina M, Kirwan D, Sheen P: A New Approach for Pyrazinamide Susceptibility Testing in Mycobacterium tuberculosis. Microb Drug Resist. 2012, 18 (4): 372-375. 10.1089/mdr.2011.0207.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.